MetaCap

Adlai Nortye Group (ANL) vs Annexon (ANNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adlai Nortye Group (ANL) has outperformed Annexon (ANNX) over the past year, gaining 533.3% versus a loss of 27.4%. Annexon is the larger company by market cap ($591.4 million vs $550.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANL+533.33%ANNX-27.40%
+1188%+547%-93%
Nov 21, 20251 yearNov 20, 2026
ANL-43.00%ANNX+31.36%
+232%+62%-109%
Sep 25, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANL versus ANNX key metrics
MetricANLANNX
Share price$8.55$3.10
Market cap$550.60M$591.37M
1-day change-5.63%-9.09%
YTD return+502.11%-38.25%
1-year return+533.33%-27.40%
5-year return—-77.37%
EPS (TTM)$-0.66$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-51.87M$-206.69M
52-week high$17.25$7.18
52-week low$0.879$3.07
Distance from 52-week high-50.43%-56.82%
Analyst consensusstrong_buybuy
Avg. price target upside+245.03%+448.39%
Average volume244.74K3.36M
Shares outstanding58.73M190.76M
Employees10997
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANL has outperformed ANNX by 560.7 percentage points over the past year.

About Adlai Nortye Group

ANL stock →

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees

About Annexon

ANNX stock →

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees

ANL vs ANNX FAQ

Which is bigger, Adlai Nortye Group or Annexon?

Annexon (ANNX) is larger, with a market capitalization of $591.37M compared with $550.60M for Adlai Nortye Group (ANL).

Which stock has performed better over the past year, ANL or ANNX?

ANL returned +533.33% over the past 12 months, compared with -27.40% for ANNX (price return, excluding dividends). Past performance does not predict future results.

Are Adlai Nortye Group and Annexon in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons